Walgreens Boots Alliance — Q2 2022 Earnings Presentation
37 slides from Walgreens Boots Alliance's earnings presentation, Mar 31, 2022
Slide 1: Fiscal 2022 Second Quarter Results
Fiscal 2022 Second Quarter Results March 31, 2022 © 2022 Walgreens Boots Alliance, Inc. All rights reserved. 1
Slide 2: Safe Harbor and Non-GAAP
Safe Harbor and Non-GAAP Cautionary Note Regarding Forward-Looking Statements: All statements in this presentation that are not historical are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitat
Slide 3: Takeaways
Takeaways • Strong Execution Across Segments • Adj. EPS +26.5% in constant Fx • Robust comparable sales growth across U.S. Pharmacy, U.S. Retail, and Boots UK Retail • Continued Progress on Our Strategic Initiatives • Walgreens Health on pace toward KPI milestones • Strategic review of Boots busines
Slide 4: Leading the Fight Against Pandemic
Leading the Fight Against Pandemic >62 million vaccinations administered to date >12 million boosters administered to date Vaccinations Largest pediatric vaccine provider in the pharmacy channel >27 million COVID-19 tests completed to date Launched the Walgreens COVID-19 Index to advance rapid detec
Slide 5: To Be the Leading Partner in Reimagining Local Healthcare and Wellbeing for All
To Be the Leading Partner in Reimagining Local Healthcare and Wellbeing for All Strategic Priorities: 1. Transform and Align the Core 2. Build Our Next Growth Engine with Consumer-Centric Healthcare Solutions 3. Focus the Portfolio; Optimize Capital Allocation 4. Build a High-Performance Culture and
Slide 6: Recent Progress on Strategic Priorities
Recent Progress on Strategic Priorities U.S. digital sales +38% in 2Q (116% on a 2-year basis), with 3.9 million same-day pick-up orders 96.1 million myWalgreens members at quarter-end, up 10.9 million since 4Q 102 VillageMD co-located clinics now open, on track toward 200+ by the end of CY22
Slide 7: Delivering and Enabling Value-Based Care Through Consumer-Centric Solutions
Delivering and Enabling Value-Based Care Through Consumer-Centric Solutions Health Corners Walgreens Health Consumer App and Marketplace Leveraging Our Strong Footprint, Deep Patient Relationships, and Independent Partnerships with Payors and Providers to Improve Outcomes and Lower Costs Along the C
Slide 8: Executing to Build Our Growth Engine
Executing to Build Our Growth Engine 128% Pro Forma Sales Growth for Walgreens Health Segment in 2Q Health Expansion into new markets including First 11 Health Corners open with Blue Shield Boston, Massachusetts; Jacksonville, Florida; Contract wins with two significant health of California; next 9
Slide 9: WBA Financial Performance
WBA Financial Performance © 2022 Walgreens Boots Alliance, Inc. All rights reserved. 9
Slide 10: 2Q 2022 Financial Highlights
2Q 2022 Financial Highlights • Adj. EPS $1.59, +26.5% above prior year in constant Fx • Second quarter performance driven by strong execution in COVID-19 vaccine and testing delivery, U.S. retail sales growth, and continued recovery in International segment performance, partly offset by Walgreens He
Slide 11: 2Q 2022 Financial Highlights
2Q 2022 Financial Highlights Reported Fx Constant Fx Continuing operations 2Q22 $ in millions (except EPS) B/(W) vs. 2Q21 B/(W) vs. 2Q21 Sales $33,756 + 3.0% + 3.8% Operating income GAAP $1,246 + 49.7% Adjusted $1,657 + 35.3% + 35.9% Net earnings GAAP $883 - 4.1% Adjusted $1,377 + 25.8% + 26.4% EPS
Slide 12: First Half FY22 Financial Highlights
First Half FY22 Financial Highlights Reported Fx Constant Fx Continuing operations 1H22 $ in millions (except EPS) B/(W) vs. 1H21 B/(W) vs. 1H21 Sales $67,656 + 5.4% + 5.7% Operating income GAAP $2,529 + $2,231 Adjusted $3,434 + 41.8% + 42.1% Net earnings GAAP $4,463 + $3,932 Adjusted $2,833 + 38.7%
Slide 13: United States – Financials
United States – Financials $ in millions 2Q22 B/(W) vs. 2Q21 1H22 B/(W) vs. 1H21 Sales $27,667 + 1.2% $55,699 + 2.2% Adj. gross profit $6,487 + 13.7% $12,855 + 13.0% Adj. SG&A % of sales 18.3% - 1.2%p 17.7% - 0.7%p Adj. operating income $1,588 + 36.5% $3,277 + 41.4% Adj. operating margin1 5.2% + 1.4
Slide 14: United States – Pharmacy
United States – Pharmacy 2Q 2Q 1H 1H 2Q22 vs. 2Q21 Total Comparable Total Comparable Pharmacy sales - 3.3% + 7.3% - 1.1% + 7.1% Prescriptions + 3.9% + 4.7% + 4.7% + 5.4% • Comparable pharmacy sales grew +7.3% in the quarter • Comparable scripts +4.7%, benefitting from COVID-19 vaccinations by 275 bp
Slide 15: United States – Retail
United States – Retail 2Q22 vs. 2Q21 2Q22 1H22 Total retail sales + 14.5% + 12.4% Comparable retail sales + 14.7% + 12.8% • 2Q comp retail sales +14.7%, or excl. tobacco +15.7%; up mid-teens vs. pre-COVID levels ⎯ Transactions +9.5% and basket size +4.7% ⎯ Strength in Health & Wellness +43.3% led by
Slide 16: International – Financials
International – Financials Constant Fx Constant Fx Continuing operations 2Q22 B/(W) vs. 2Q21 1H22 B/(W) vs. 1H21 $ in millions Sales $5,563 + 7.5% $11,381 + 19.3% Adj. gross profit $1,206 + 15.2% $2,413 + 16.6% Adj. SG&A % of sales 17.6% - 0.1%p 17.8% + 1.5%p Adj. operating income $226 + 60.7% $389
Slide 17: Boots UK – Financials
Boots UK – Financials 2Q22 vs. 2Q21 (constant Fx) 2Q22 1H22 Pharmacy comp. sales + 3.6% + 6.2% Retail comp. sales + 22.0% + 19.2% • Pharmacy comp. sales +3.6%, reflecting higher levels of pharmacy services • Boots growing retail market share across all categories, led by Beauty • Strengthening retai
Slide 18: Walgreens Health – Financials
Walgreens Health – Financials Health $ in millions 2Q22 B/(W) vs. 2Q21 1H22 B/(W) vs. 1H21 Sales $527 + $527 $577 + $577 Adj. gross profit $15 + $15 $36 + $36 Adj. SG&A ($92) ($81) ($126) ($111) Adj. operating income ($77) ($66) ($90) ($76) • VillageMD sales of $446M in 2Q, +145% on a pro forma basi
Slide 19: Walgreens Health – Key Metrics
Walgreens Health – Key Metrics Health Current Status CY22 Goal Lives 1.9M 2M+ Partners (Payor/Provider) 2 5 Sites of Care: Health Corners 47 100+ VillageMD Co-Located Clinics 102 200+ 2Q22 FY22 Goal Sales (Reported) $577M YTD $2.2B Pro Forma Sales Growth YOY: VillageMD 145% Shields 63% Total Walgree
Slide 20: Cash Flow
Cash Flow B/(W) $ in millions 1H22 vs. 1H21 Operating cash flow $2,184 ($372) Cash capital expenditure ($870) ($178) Free cash flow $1,314 ($550) • YTD cash generation of $2.2B in operating cash flow and $1.3B of free cash flow • Free cash flow was adversely impacted vs. prior year due to decline of
Slide 21: Maintaining Full Year Guidance
Maintaining Full Year Guidance October 2021 January 2022 March 2022 Adj. EPS Growth (Constant Fx) FY Guidance FY Guidance FY Guidance Base + 4% + 5-7% + 6-8% Healthcare Organic (3)% (3)% (3)% Healthcare M&A (1)% (1)% (2)% Adjusted EPS Flat LSD Growth LSD Growth • Expecting ~31 million vaccinations i
Slide 22: Takeaways
Takeaways • Strong Execution Across Segments • Adj. EPS +26.5% in constant Fx • Robust comparable sales growth across U.S. Pharmacy, U.S. Retail, and Boots UK Retail • Continued Progress on Our Strategic Initiatives • Walgreens Health on pace toward KPI milestones • Strategic review of Boots busines
Slide 23: © 2022 Walgreens Boots Alliance, Inc. All rights reserved.
© 2022 Walgreens Boots Alliance, Inc. All rights reserved. 23
Slide 24: Endnotes
Endnotes • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures • The company presents certain information related to current period operating results in “constant currency,” which is a non-GAAP financial measure. These amounts are calculated by translating
Slide 25: Appendix
Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente
Slide 26: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended February 28, Change vs. 2Q21 Six months ended February 28, Change vs. 1H21 2022 2021 Amount Percent 2022 2021 Amount Percen
Slide 27: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended February 28, Change vs. 2Q21 Six months ended February 28, Change vs. 1H21 2022 2021 Amount Percent 2022 2021 Amount Percen
Slide 28: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) DILUTED NET EARNINGS (LOSS) PER SHARE Three months ended February 28, Change vs. 2Q21 Six months ended February 28, Change vs. 1H21 2022 2021 Amount Percent 2022 2021 Am
Slide 29: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Transformational Cost Management Program charges are costs associated with a formal restructuring plan. These charges are primarily recorded within selling, general an
Slide 30: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended February 28, 2022 Walgreens Boots United States1 International Walgreens Health Corporate and Other Alliance, Inc. Sales $ 27,667 $ 5,56
Slide 31: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended February 28, 2021 Walgreens Boots United States1 International Walgreens Health3 Corporate and Other Alliance, Inc. Sales $ 27,344 $ 5,4
Slide 32: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Six months ended February 28, 2022 Walgreens Boots United States1 International Walgreens Health Corporate and Other Alliance, Inc. Sales $ 55,699 $ 11,381
Slide 33: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Six months ended February 28, 2021 Walgreens Boots United States1 International Walgreens Health3 Corporate and Other Alliance, Inc. Sales $ 54,507 $ 9,709
Slide 34: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) 1 Operating income (loss) for United States includes equity earnings (loss) in AmerisourceBergen. As a result of the two-month reporting lag, operating income (loss) for
Slide 35: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS (LOSS) IN AMERISOURCEBERGEN Three months ended February 28, Six months ended February 28, 2022 2021 2022 2021 Equity earnings (loss) in Ame
Slide 36: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended February 28, 2022 Three months ended February 28, 2021 Earnings before Earnings before income tax Income tax
Slide 37: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended February 28, Six months ended February 28, 2022 2021 2022 2021 Net cash provided by operating activities (GAAP) $ 1,085 $
Walgreens Boots Alliance — Q2 2022 Earnings Presentation on 6ix